Comorbidity of age-related macular degeneration with Alzheimer’s disease: A histopathologic case-control study
Autoři:
Gordon J. Smilnak aff001; John R. Deans aff001; P. Murali Doraiswamy aff002; Sandra Stinnett aff001; Heather E. Whitson aff003; Eleonora M. Lad aff001
Působiště autorů:
Department of Ophthalmology, Duke University Medical Center, Durham, NC, United States of America
aff001; Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, United States of America
aff002; Department of Internal Medicine, Division of Geriatrics, Duke University Medical Center, Durham, NC, United States of America
aff003
Vyšlo v časopise:
PLoS ONE 14(9)
Kategorie:
Research Article
doi:
https://doi.org/10.1371/journal.pone.0223199
Souhrn
Introduction
Previous studies evaluating the association between clinically diagnosed Alzheimer’s disease (AD) and age-related macular degeneration (AMD) have generated conflicting results. This study is the first to assess whether AMD prevalence is higher in AD patients than non-AD controls by using histopathology to definitively diagnose AD.
Methods
This was a retrospective case-control study utilizing diagnostic information extracted from autopsy reports of patients age 75 and above, including 115 with a neuropathological diagnosis of AD and 57 age-matched normal controls.
Results
The rate of AMD was not significantly higher in AD cases (53.0%) than in controls (59.6%) (z = 0.820, p = 0.794). AMD severity as determined by Sarks score was similar between AD patients and controls (χ2 = 2.96, p = 0.706). There was also no significant association between Braak stage of AD severity and AMD (χ2 = 4.55, p = 0.602).
Discussion
No significant effect of AD diagnosis or pathologic severity on AMD comorbidity was found, suggesting that any shared mechanisms between AMD and AD may be nondeterministic.
Klíčová slova:
Alzheimer's disease – Alzheimer's disease diagnosis and management – Autopsy – Cognitive impairment – Eye diseases – Eyes – Glaucoma – Macular degeneration
Zdroje
1. Kaarniranta K, Salminen A, Haapasalo A, Soininen H, Hiltunen M. Age-related macular degeneration (AMD): Alzheimer's disease in the eye? Journal of Alzheimer's disease: JAD. 2011;24(4):615–31. Epub 2011/02/08. doi: 10.3233/JAD-2011-101908 21297256.
2. Sivak JM. The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease. Investigative ophthalmology & visual science. 2013;54(1):871–80. Epub 2013/02/01. doi: 10.1167/iovs.12-10827 23364356.
3. Jindal V. Interconnection between brain and retinal neurodegenerations. Molecular neurobiology. 2015;51(3):885–92. Epub 2014/05/16. doi: 10.1007/s12035-014-8733-6 24826919.
4. Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Experimental eye research. 2004;78(2):243–56. Epub 2004/01/20. doi: 10.1016/j.exer.2003.10.011 14729357.
5. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(18):11830–5. Epub 2002/08/22. doi: 10.1073/pnas.192203399 12189211; PubMed Central PMCID: PMC129354.
6. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Progress in retinal and eye research. 2001;20(6):705–32. Epub 2001/10/06. 11587915.
7. McGeer PL, Klegeris A, Walker DG, Yasuhara O, McGeer EG. Pathological proteins in senile plaques. The Tohoku journal of experimental medicine. 1994;174(3):269–77. Epub 1994/11/01. doi: 10.1620/tjem.174.269 7761992.
8. Klaver CC, Ott A, Hofman A, Assink JJ, Breteler MM, de Jong PT. Is age-related maculopathy associated with Alzheimer's Disease? The Rotterdam Study. American journal of epidemiology. 1999;150(9):963–8. Epub 1999/11/05. doi: 10.1093/oxfordjournals.aje.a010105 10547142.
9. Woo SJ, Park KH, Ahn J, Choe JY, Jeong H, Han JW, et al. Cognitive impairment in age-related macular degeneration and geographic atrophy. Ophthalmology. 2012;119(10):2094–101. Epub 2012/06/19. doi: 10.1016/j.ophtha.2012.04.026 22705343.
10. Williams MA, Silvestri V, Craig D, Passmore AP, Silvestri G. The prevalence of age-related macular degeneration in Alzheimer's disease. Journal of Alzheimer's disease: JAD. 2014;42(3):909–14. Epub 2014/07/16. doi: 10.3233/JAD-140243 25024309.
11. Keenan TD, Goldacre R, Goldacre MJ. Associations between age-related macular degeneration, Alzheimer disease, and dementia: record linkage study of hospital admissions. JAMA ophthalmology. 2014;132(1):63–8. Epub 2013/11/16. doi: 10.1001/jamaophthalmol.2013.5696 24232933.
12. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2012;8(1):1–13. Epub 2012/01/24. doi: 10.1016/j.jalz.2011.10.007 22265587; PubMed Central PMCID: PMC3266529.
13. Pham TQ, Kifley A, Mitchell P, Wang JJ. Relation of age-related macular degeneration and cognitive impairment in an older population. Gerontology. 2006;52(6):353–8. Epub 2006/08/12. doi: 10.1159/000094984 16902306.
14. Wong TY, Klein R, Nieto FJ, Moraes SA, Mosley TH, Couper DJ, et al. Is early age-related maculopathy related to cognitive function? The Atherosclerosis Risk in Communities Study. American journal of ophthalmology. 2002;134(6):828–35. Epub 2002/12/10. doi: 10.1016/s0002-9394(02)01672-0 12470750.
15. Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends in biotechnology. 2011;29(1):26–32. Epub 2010/10/26. doi: 10.1016/j.tibtech.2010.09.007 PubMed Central PMCID: PMC3016495. 20971518
16. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. Journal of neuropathology and experimental neurology. 2012;71(4):266–73. Epub 2012/03/23. doi: 10.1097/NEN.0b013e31824b211b 22437338; PubMed Central PMCID: PMC3331862.
17. Curtis LH, Hammill BG, Qualls LG, DiMartino LD, Wang F, Schulman KA, et al. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries. American journal of ophthalmology. 2012;153(6):1116–24.e1. Epub 2012/02/11. doi: 10.1016/j.ajo.2011.11.032 22321802.
18. Thorpe CT, Thorpe JM, Kind AJ, Bartels CM, Everett CM, Smith MA. Receipt of monitoring of diabetes mellitus in older adults with comorbid dementia. Journal of the American Geriatrics Society. 2012;60(4):644–51. Epub 2012/03/21. doi: 10.1111/j.1532-5415.2012.03907.x 22428535; PubMed Central PMCID: PMC3325373.
19. Lad EM, Cousins SW, Van Arnam JS, Proia AD. Abundance of infiltrating CD163+ cells in the retina of postmortem eyes with dry and neovascular age-related macular degeneration. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2015;253(11):1941–5. Epub 2015/07/08. doi: 10.1007/s00417-015-3094-z 26148801; PubMed Central PMCID: PMC5203931.
20. Mott RT, Hulette CM. Neuropathology of Alzheimer's disease. Neuroimaging clinics of North America. 2005;15(4):755–65, ix. Epub 2006/01/31. doi: 10.1016/j.nic.2005.09.003 16443488.
21. Chan KY, Wang W, Wu JJ, Liu L, Theodoratou E, Car J, et al. Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990–2010: a systematic review and analysis. Lancet (London, England). 2013;381(9882):2016–23. Epub 2013/06/12. doi: 10.1016/S0140-6736(13)60221-4 23746902.
22. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues in clinical neuroscience. 2009;11(2):111–28. Epub 2009/07/10. 19585947; PubMed Central PMCID: PMC3181909.
23. Sarks SH. Ageing and degeneration in the macular region: a clinico-pathological study. The British journal of ophthalmology. 1976;60(5):324–41. Epub 1976/05/01. doi: 10.1136/bjo.60.5.324 952802; PubMed Central PMCID: PMC1042725.
24. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta neuropathologica. 1991;82(4):239–59. Epub 1991/01/01. doi: 10.1007/bf00308809 1759558.
25. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479–86. Epub 1991/04/01. doi: 10.1212/wnl.41.4.479 2011243.
26. Margeta MA, Lad EM, Proia AD. CD163+ macrophages infiltrate axon bundles of postmortem optic nerves with glaucoma. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2018;256(12):2449–56. Epub 2018/08/04. doi: 10.1007/s00417-018-4081-y 30073622; PubMed Central PMCID: PMC6221945.
27. Malek G, Lad EM. Emerging roles for nuclear receptors in the pathogenesis of age-related macular degeneration. Cell Mol Life Sci. 2014;71(23):4617–36. Epub 2014/08/27. doi: 10.1007/s00018-014-1709-x 25156067; PubMed Central PMCID: PMC4233183.
28. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. American journal of ophthalmology. 2004;137(3):486–95. Epub 2004/03/12. doi: 10.1016/j.ajo.2003.11.069 15013873.
29. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Archives of ophthalmology (Chicago, Ill: 1960). 2003;121(4):519–26. Epub 2003/04/16. doi: 10.1001/archopht.121.4.519 12695249.
30. Whitson HE, Ansah D, Sanders LL, Whitaker D, Potter GG, Cousins SW, et al. Comorbid cognitive impairment and functional trajectories in low vision rehabilitation for macular disease. Aging clinical and experimental research. 2011;23(5–6):343–50. Epub 2012/04/25. 22526069; PubMed Central PMCID: PMC3338208.
31. Rogers MA, Langa KM. Untreated poor vision: a contributing factor to late-life dementia. American journal of epidemiology. 2010;171(6):728–35. Epub 2010/02/13. doi: 10.1093/aje/kwp453 20150357; PubMed Central PMCID: PMC2842219.
32. Logue MW, Schu M, Vardarajan BN, Farrell J, Lunetta KL, Jun G, et al. Search for age-related macular degeneration risk variants in Alzheimer disease genes and pathways. Neurobiology of aging. 2014;35(6):1510.e7–18. Epub 2014/01/21. doi: 10.1016/j.neurobiolaging.2013.12.007 24439028; PubMed Central PMCID: PMC3961547.
33. Le Fur I, Laumet G, Richard F, Fievet N, Berr C, Rouaud O, et al. Association study of the CFH Y402H polymorphism with Alzheimer's disease. Neurobiology of aging. 2010;31(1):165–6. Epub 2008/04/25. doi: 10.1016/j.neurobiolaging.2008.03.003 18433936.
34. Williams MA, McKay GJ, Carson R, Craig D, Silvestri G, Passmore P. Age-Related Macular Degeneration-Associated Genes in Alzheimer Disease. Am J Geriatr Psychiatry. 2015;23(12):1290–6. Epub 2015/10/01. doi: 10.1016/j.jagp.2015.06.005 26419733.
35. Turunen M, Vepsalainen S, Makinen P, Helisalmi S, Haapasalo A, Soininen H, et al. No association between high temperature requirement 1 (HTRA1) gene polymorphisms and Alzheimer's disease. Neurobiology of aging. 2011;32(3):547.e7-9. Epub 2009/09/29. doi: 10.1016/j.neurobiolaging.2009.08.010 19783326.
36. Adams MK, Simpson JA, Richardson AJ, English DR, Aung KZ, Makeyeva GA, et al. Apolipoprotein E gene associations in age-related macular degeneration: the Melbourne Collaborative Cohort Study. American journal of epidemiology. 2012;175(6):511–8. Epub 2012/02/14. doi: 10.1093/aje/kwr329 22328704.
37. Ding JD, Johnson LV, Herrmann R, Farsiu S, Smith SG, Groelle M, et al. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(28):E279–87. Epub 2011/06/22. doi: 10.1073/pnas.1100901108 21690377; PubMed Central PMCID: PMC3136266.
38. Walker J. Latest Experimental Alzheimer’s Drug Fails Testing. The Wall Street Journal. 2019 March 21, 2019.
39. Servick K. Another major drug candidate targeting the brain plaques of Alzheimer’s disease has failed. Science Magazine. 2019 March 21, 2019.
40. GEN. Genentech’s crenezumab fails two Phase III trials in Alzheimer’s. Genetic Engineering & Biotechnology News. 2019 January 30, 2019 (col. 2019).
41. Gupta N, Greenberg G, de Tilly LN, Gray B, Polemidiotis M, Yucel YH. Atrophy of the lateral geniculate nucleus in human glaucoma detected by magnetic resonance imaging. The British journal of ophthalmology. 2009;93(1):56–60. Epub 2008/08/14. doi: 10.1136/bjo.2008.138172 18697810; PubMed Central PMCID: PMC2605243.
42. Yucel Y, Gupta N. Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration. Progress in brain research. 2008;173:465–78. Epub 2008/10/22. doi: 10.1016/S0079-6123(08)01132-1 18929128.
43. Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer's disease. European neurology. 2002;47(3):165–8. Epub 2002/03/27. doi: 10.1159/000047976 11914555.
44. Tamura H, Kawakami H, Kanamoto T, Kato T, Yokoyama T, Sasaki K, et al. High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. Journal of the neurological sciences. 2006;246(1–2):79–83. Epub 2006/03/28. doi: 10.1016/j.jns.2006.02.009 16564058.
45. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791–800. Epub 2002/06/27. doi: 10.1212/wnl.58.12.1791 12084879.
46. Marcus C, Mena E, Subramaniam RM. Brain PET in the diagnosis of Alzheimer's disease. Clin Nucl Med. 2014;39(10):e413–e26. doi: 10.1097/RLU.0000000000000547 25199063.
47. Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology. 2012;119(3):571–80. Epub 2011/12/20. doi: 10.1016/j.ophtha.2011.09.027 22176800.
48. Skoog I, Gustafson D. Update on hypertension and Alzheimer's disease. Neurological research. 2006;28(6):605–11. Epub 2006/09/02. doi: 10.1179/016164106X130506 16945211.
49. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Archives of neurology. 2004;61(5):661–6. Epub 2004/05/19. doi: 10.1001/archneur.61.5.661 15148141.
50. Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC ophthalmology. 2010;10:31. Epub 2010/12/15. doi: 10.1186/1471-2415-10-31 21144031; PubMed Central PMCID: PMC3009619.
51. Ong SS, Doraiswamy PM, Lad EM. Controversies and Future Directions of Ocular Biomarkers in Alzheimer Disease. JAMA neurology. 2018;75(6):650–1. Epub 2018/05/02. doi: 10.1001/jamaneurol.2018.0602 29710250.
52. Ong SS, Proia AD, Whitson HE, Farsiu S, Doraiswamy PM, Lad EM. Ocular amyloid imaging at the crossroad of Alzheimer's disease and age-related macular degeneration: implications for diagnosis and therapy. Journal of neurology. 2018. Epub 2018/08/30. doi: 10.1007/s00415-018-9028-z 30155741.
Článek vyšel v časopise
PLOS One
2019 Číslo 9
- S diagnostikou Parkinsonovy nemoci může nově pomoci AI nástroj pro hodnocení mrkacího reflexu
- Je libo čepici místo mozkového implantátu?
- Pomůže v budoucnu s triáží na pohotovostech umělá inteligence?
- AI může chirurgům poskytnout cenná data i zpětnou vazbu v reálném čase
- Nová metoda odlišení nádorové tkáně může zpřesnit resekci glioblastomů
Nejčtenější v tomto čísle
- Graviola (Annona muricata) attenuates behavioural alterations and testicular oxidative stress induced by streptozotocin in diabetic rats
- CH(II), a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer’s disease
- Comparison between Aptima Assays (Hologic) and the Allplex STI Essential Assay (Seegene) for the diagnosis of Sexually transmitted infections
- Assessment of glucose-6-phosphate dehydrogenase activity using CareStart G6PD rapid diagnostic test and associated genetic variants in Plasmodium vivax malaria endemic setting in Mauritania
Zvyšte si kvalifikaci online z pohodlí domova
Všechny kurzy